Global medtech company Vantive has announced plans to develop a new €150 million manufacturing facility in Ħal Far, Malta, strengthening the island’s growing life sciences and medical technology cluster. The purpose-built plant will focus on kidney care and vital organ support products, expanding Vantive’s European production capacity and supporting the company’s strategy to advance therapies for patients with kidney disease and other critical conditions. The investment is set to create hundreds of skilled jobs once operational, including roles in advanced manufacturing, engineering, quality, and supply chain, while also generating significant employment during the construction and fit-out phase.
Vantive, formerly part of Baxter’s kidney care business, was established as an independent company to accelerate innovation in renal care and organ support. The Ħal Far facility will incorporate state-of-the-art cleanroom production, automation, and digital manufacturing systems to produce high-precision medical devices and disposables used in dialysis and acute therapies. Locating the plant in Malta’s established industrial zone at Ħal Far provides access to a skilled workforce, a supportive regulatory environment, and proximity to European and global markets. The project also benefits from Malta’s position as a hub for pharmaceutical and medtech investment, with government agencies emphasizing the sector’s role in economic diversification and high-value employment.
The €150 million commitment represents one of the largest recent medtech investments in Malta and aligns with national efforts to attract advanced manufacturing that delivers sustainable growth. Construction is expected to begin following planning approvals, with production targeted to commence in phases over the coming years. Vantive said the facility will complement its existing global network and help meet rising demand for kidney care solutions, driven by increasing prevalence of chronic kidney disease worldwide. The company also highlighted Malta’s strong track record in medical technology, skilled talent pool, and collaborative ecosystem as key factors in selecting Ħal Far for the new site.
